Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.

MLA

Fitz-Patrick, David, et al. “Safety and Efficacy of Verinurad, a Selective URAT1 Inhibitor, for the Treatment of Patients with Gout and/or Asymptomatic Hyperuricemia in the United States and Japan: Findings from Two Phase II Trials.” Modern Rheumatology, vol. 29, no. 6, Nov. 2019, pp. 1042–52. EBSCOhost, https://doi.org/10.1080/14397595.2018.1538003.

APA

Fitz-Patrick, D., Roberson, K., Kiyoshi Niwa, Takabumi Fujimura, Koji Mori, Jesse Hall, Xiaohong Yan, Zancong Shen, Sha Liu, Yasushi Ito, & Baumgartner, S. (2019). Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials. Modern Rheumatology, 29(6), 1042–1052. https://doi.org/10.1080/14397595.2018.1538003

Chicago

Fitz-Patrick, David, Kent Roberson, Kiyoshi Niwa, Takabumi Fujimura, Koji Mori, Jesse Hall, Xiaohong Yan, et al. 2019. “Safety and Efficacy of Verinurad, a Selective URAT1 Inhibitor, for the Treatment of Patients with Gout and/or Asymptomatic Hyperuricemia in the United States and Japan: Findings from Two Phase II Trials.” Modern Rheumatology 29 (6): 1042–52. doi:10.1080/14397595.2018.1538003.